Description
Evergraf 0.25mg consists of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.Evergraf 0.25mg tablets is not a curable medication, which helps to slow their spreading into the body.
Indication
Primarily Evergraf 0.25mg tablets indicated for the treatment* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.
Mechanism Of Action
Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis
Dosage
Evergraf 0.25mg tablets should be given with or without food.The dosage regimen of Evergraf 0.25mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.
Precautions
Lymphomas:The developed hazard of skin cancers, the patient may protect from UV light
Serious infections:
Patients getting Evergraf 0.25mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.
Hepatic artery thrombosis:
Evergraf 0.25mg therapy should not be recommended in liver transplant patients,
Nephrotoxicity:
While using Evergraf 0.25mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.
Drug Interaction
Evergraf 0.25mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.Interaction of Evergraf 0.25mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.25mg with cyclosporine will be increasing the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.25mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.
Pregnancy
Pregnancy category of Everolimus CIn patients, Evergraf 0.25mg is used only after knowing the benefits to the mother exceed the risk to the fetus.
Lactation
Breastfeeding should not be suggestedStorage
Evergraf 0.25mg tablet store at 25°C.Store the medicine away from moisture, heat, and light
Missed Dose
In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them.Thereby missed dose should be avoided and follow the regular dosing schedule.
FOR MORE INFORMATION:
EMAIL:
applepharmaceutical@gmail.com
No comments:
Post a Comment